Latest News

Tuesday, February 13, 2018

Fibromyalgia Associated With Corneal Sensitivity, Ocular Pain

Patients with fibromyalgia have increased eye sensitivity and pain, researchers from Turkey report, according to a report from Medscape. “Patients with fibromyalgia have increased corneal sen…

Read the full story

Monday, February 12, 2018

Precision Lens Says It Will Fight Federal Allegations of Using Illegal Incentives

IOL distributor Precision Lens is vowing to fight a Justice Department lawsuit alleging the firm knowingly provided illegal incentives to eye surgeons like expensive hunting trips and vacations in ord…

Read the full story

Monday, February 12, 2018

Aerpio Pharmaceuticals Completes Patient Enrollment in a Phase 2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy

Aerpio Pharmaceuticals announced the completion of patient enrollment in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead …

Read the full story

Monday, February 12, 2018

Icon Bioscience Receives FDA Approval for Dexycu Drug Therapy for Treating Inflammation Associated with Cataract Surgery

Icon Bioscience announced that the FDA has approved the company's new drug application for Dexycu (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammat…

Read the full story

Monday, February 12, 2018

Trump Administration Proposes Changes to Lower Drug Costs

The administration of US President Donald Trump on Friday released a white paper unveiling a number of proposals seeking to target rising prescription drug prices. The proposed changes inclu…

Read the full story

Monday, February 12, 2018

Santen Presents Phase 1/2 Data on DE-122 (Carotuximab) in Patients with Refractory Wet AMD

Santen announced that the topline results from the phase 1/2 study of DE-122 (carotuximab) for refractory wet age-related macular degeneration (AMD) were presented at the 15th Annual Angiogenesis, Exu…

Read the full story

Monday, February 12, 2018

Phase 2 Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People with DME

Genentech announced encouraging results from the phase 2 BOULEVARD study. In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 demonstrated clinically meani…

Read the full story

Friday, February 09, 2018

NEI Support Paved Early Pathway for Novel Glaucoma Therapies

The recent approval of two novel medications for glaucoma -- the first new medications for the disorder in nearly 18 years -- are fruit born from decades of foundational scientific research suppor…

Read the full story

Friday, February 09, 2018

Q Biomed Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

Q BioMed has announced an exclusive option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the fea…

Read the full story

Friday, February 09, 2018

Researchers Design a New Intracorneal Inlay to Correct Presbyopia

Researchers at the Universitat Politècnica de València, University of Valencia, Instituto de Investigación Sanitaria La Fe and the companies AJL Ophthalmic SA and Aiken-Tecnolog…

Read the full story

Friday, February 09, 2018

ASCRS Announces 2018 Ophthalmology Hall of Fame Inductees

The American Society of Cataract and Refractive Surgery (ASCRS) has announced that it will induct I. Howard Fine, MD, and the late David Maurice, PhD, into the ASCRS Ophthalmology Hall of Fame on Satu…

Read the full story

Thursday, February 08, 2018

Study: Glaukos iStent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma

Glaukos announced that a study published in the January 2018 issue of the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent implanted during cataract surgery in patients wi…

Read the full story

Thursday, February 08, 2018

Follow-up Insufficient After Retinal Infarction

Patients with retinal infarction appear to be falling through the cracks when it comes to appropriate evaluation for risk for further stroke, according to a report in Medscape. A new study shows th…

Read the full story

Wednesday, February 07, 2018

Oculus Pentacam AXL is Now Linked to the IOLcompass Pro Guidance System and TruePlan

Oculus and Leica Microsystems have informed surgeons that the new link to Leica’s Pro Guidance system and TrueVisions’ TruePlan is now ready to be purchased. As recently published, Oculus …

Read the full story

Wednesday, February 07, 2018

Allergan's Profit Beats; Migraine Drug Succeeds in Key Study

Allergan on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study. The key data could ease some …

Read the full story
Load More
 Stock Price  Change 
 ADVM $7.08  0.35% 
 Aerie Pharmaceuticals, Inc. $52.75  0.38% 
 Akorn, Inc. $31.98  -0.44% 
 Alimera Sciences, Inc. $1.06  -2.75% 
 Allergan $162.84  0.04% 
 Applied Genetic Technologies $3.95  -0.13% 
 Bayer $30.19  0.97% 
 Can-Fite Biopharma $2.09  3.47% 
 Carl Zeiss Meditec $46.04  -6.77% 
 Clearside Biomedical $6.01  4.15% 
 Cooper Companies, Inc. $225.64  -0.49% 
 Eleven Biotherapeutics $0.85  4.94% 
 Escalon Medical Corp. $0.20  4.74% 
 Essilor International $107.65  1.32% 
 Glaukos $29.52  1.58% 
 Imprimis Pharmaceuticals, Inc. $1.62  1.24% 
 Inotek Pharmaceuticals $3.03  -0.33% 
 IRIDEX Corporation $7.15  0.00% 
 Johnson & Johnson $129.63  0.08% 
 Merck & Company, Inc. $55.53  1.46% 
 NicOx $8.88  -0.56% 
 NovaBay Pharmaceuticals, Inc. $3.65  4.29% 
 Novartis AG Common Stock $84.13  1.93% 
 Ocular Therapeutix $5.01  -0.30% 
 Ophthotech Corporation $2.77  -0.90% 
 Quantel $6.40  -8.57% 
 Regeneron $339.09  0.81% 
 Roche $29.21  0.78% 
 Second Sight Medical Products $1.77  4.95% 
 Shire $132.51  3.98% 
 Spark Therapeutics, Inc. $53.26  1.35% 
 STAAR Surgical Company $15.23  -0.81% 
 TearLab Corporation $0.33  -3.51% 
 Thrombogenics $4.15  1.22% 
 Valeant Pharmaceuticals $17.95  0.90% 
 Xoma $25.07  -1.53%